The pharmacokinetics of lamivudine in patients with impaired hepatic function

European Journal of Clinical Pharmacology

Volumn 54, Issue 4, 1998, Pages 363-366

  Johnson, M A ^a   Horak, J ^b   Breuel, P ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Pharmacon Research   (Germany)

Author keywords

Hepatic impairment; Lamivudine

Indexed keywords

LAMIVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; CAFFEINE; FEMALE; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 0031818475     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050476     Document Type: Article

References (14)

1. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS (1987) The toxicity of azidothymidine (AZT) in the treatment of AIDS and AIDS-related complex. A double-blind placebo-controlled trial. N Engl J Med 317: 192-197
2. Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, Wills RJ, McAtee N, Fischl MA, Dubinsky R, McNeely MC (1988) Phase 1 studies of 2′3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1: 76-78
3. Cooley RP, Kunches LM, Sanders CA, Ritter JK, Perkins CJ, McLaren C, McCaffrey RP, Liebman HA (1990) Once daily administration of 2′3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 322: 1340-1345
4. Doong S-L, Tsai C-H, Shinazi RF, Liotta DC, Cheng Y-C (1991) Inhibition of the replication of hepatitis B virus in vitro by 2′3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 88: 8495-8499
5. Angel JB, Hussey EK, Hall ST, Donn KH, Morris DM, McCormack JP, Montaner JSG, Ruedy J (1993) Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients. Drug Invest 6: 70-74
6. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
7. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA (1996) Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 40: 1514-1519
8. Harker AJ, Evans GL, Hawley AE, Morris DM (1994) High-performance liquid chromatographic assay for 2′-deoxy-3′-thiacytidine in human serum. J Chromatogr B Biomed Sci Appl 657: 227-232
9. Beuers U, Jager F, Wahllander A, Ansari H, Kirsch CM (1991) Prognostic value of the intravenous 14C-aminopyrine breath test compared to the Child-Pugh score and serum bile acids in 84 cirrhotic patients. Digestion 50: 212-218
10. Conover WJ (1980) Practical nonparametric statistics, 2nd edn. Wiley, New York, 223-227 & 288-290
11. McLean AJ, Morgan DJ (1991) Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 21: 42-69
12. Renner E, Wietholtz H, Hugenin P, Arnaud MJ, Preisig R (1984) Caffeine: a model compound for measuring liver function. Hepatology 4: 38-46
13. Henry DA, Kitchingman G, Langman MJS (1985) 14C-Aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis. Dig Dis Sci 30: 813-818
14. Cheng WSC, Murphy TL, Smith MT, Cooksley GE, Halliday JW, Powell LW (1990) Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin Pharmacol Ther 47: 516-524